Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rilpivirine,Abacavir,Zidovudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Janssen Submits NDA to FDA for Expanded Pediatric Indication for EDURANT®
Details : Edurant (rilpivirine) is a HIV-1 specific, nonnucleoside reverse transcriptase inhibitor (NNRTI). It is being evaluated for the treatment of HIV-1 infection in children weighing 10 kg or more.
Product Name : Edurant
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2023
Lead Product(s) : Rilpivirine,Abacavir,Zidovudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rilpivirine,Zidovudine,Abacavir,Tenofovir Alafenamide,Tenofovir Disoproxil Fumarate,Emtricitabine,Lamivudine,Dolutegravir Sodium,Raltegravir Potassium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2019
Lead Product(s) : Rilpivirine,Zidovudine,Abacavir,Tenofovir Alafenamide,Tenofovir Disoproxil Fumarate,Emtricitabine,Lamivudine,Dolutegravir Sodium,Raltegravir Potassium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zidovudine,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Clinique des Maladies Infectieuses, Fann | Centre de Santé de Ziguinchor | Johnson & Johnson Innovative Medicine | Merck & Co | National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
RESIST-2: 2nd-line ART for HIV-2 Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2018
Lead Product(s) : Zidovudine,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Clinique des Maladies Infectieuses, Fann | Centre de Santé de Ziguinchor | Johnson & Johnson Innovative Medicine | Merck & Co | National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efavirenz,Tenofovir,Emtricitabine,Lamivudine,Zidovudine,Rifampicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Viatris | United States Agency for International Development
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 14, 2016
Lead Product(s) : Efavirenz,Tenofovir,Emtricitabine,Lamivudine,Zidovudine,Rifampicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Viatris | United States Agency for International Development
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Raltegravir Potassium,Zidovudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2016
Lead Product(s) : Raltegravir Potassium,Zidovudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efavirenz,Tenofovir,Emtricitabine,Lamivudine,Zidovudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Viatris
Deal Size : Inapplicable
Deal Type : Inapplicable
SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 16, 2015
Lead Product(s) : Efavirenz,Tenofovir,Emtricitabine,Lamivudine,Zidovudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Viatris
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nevirapine,Lopinavir,Ritonavir,Lamivudine,Zidovudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Ragon Institute of MGH, MIT, Harvard | Brigham and Women's Hospital | Botswana Harvard Health Partnership | University of California, San Diego
Deal Size : Inapplicable
Deal Type : Inapplicable
Early Infant HIV Treatment in Botswana
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2015
Lead Product(s) : Nevirapine,Lopinavir,Ritonavir,Lamivudine,Zidovudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Ragon Institute of MGH, MIT, Harvard | Brigham and Women's Hospital | Botswana Harvard Health Partnership | University of California, San Diego
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BILR 355 BS,Lamivudine,Zidovudine,Ritonavir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 06, 2014
Lead Product(s) : BILR 355 BS,Lamivudine,Zidovudine,Ritonavir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tipranavir,Ritonavir,Delavirdine,Zidovudine,Lamivudine,Stavudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2014
Lead Product(s) : Tipranavir,Ritonavir,Delavirdine,Zidovudine,Lamivudine,Stavudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tipranavir,Ritonavir,Zidovudine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2014
Lead Product(s) : Tipranavir,Ritonavir,Zidovudine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable